Abstract: Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diagnosis and prognosis of Alzheimer's disease and other .beta.-amyloid-related diseases, while in vitro monitoring of such secretion from cultured cells may be monitored to identify inhibitors of .beta.-amyloid production. The .beta.APP fragment may be detected using antibodies and other specific binding substances which recognize a carboxy-terminal residue on the fragment.
Type:
Grant
Filed:
May 12, 1995
Date of Patent:
February 24, 1998
Assignees:
Athena Neurosciences, Inc., Eli Lilly and Company
Inventors:
Peter A. Seubert, Dale B. Schenk, Lawrence C. Fritz
Abstract: The invention provides methods and compositions for treating neurodegeneration in mammalian cells by administering a phospholipase A2 inhibitor.
Abstract: An osmotic device is disclosed comprising an exterior coat comprising an estrogenic and a progestogenic steroid that are delivered immediately as a contraceptive pair for fertility regulation in a female, and a compartment comprising an estrogenic steroid that is delivered at a controlled rate over a prolonged period of time for fertility regulation in a female.
Type:
Grant
Filed:
December 9, 1991
Date of Patent:
April 6, 1993
Assignee:
Alza Corporation
Inventors:
Jeri D. Wright, Jerry D. Childers, Brian L. Barclay, Patrick S.-L. Wong, Linda E. Atkinson